Abnormal Lipids - Causes and Effects

Inclusion Criteria: * Therapeutic target arm * Statin treated patients with and without hypertriglyceridemia. * Statin treated patients with type 2 diabetes. * Statin treated patients with CKD stages 4 and 5. * Nerve function arm •Patients known to have severe hypertriglyceridaemia (defined as triglyceride \>5.5 mmol/l) but not known to have diabetes and matched controls. * Genetic screening arm * Patients with a documented triglyceride level of more than 10 mmol/l at any time. * Criteria for screening for FH and LAL deficiency include non-obese patients (BMI \<30) with low HDL-C (\<1.0 mmol/l male and \<1.3 mmol female), high triglycerides \>1.7 mmol/l, high total cholesterol \>6.2 or LDL cholesterol \>4.7 mmol/l; patients with raised liver alanine aminotransferase (ALT) (1.5 x above ULN) but no metabolic or viral disease or alcohol excess and patients diagnosed with NAFLD with or without hyperlipidaemia. Exclusion Criteria: * Pregnant and/or breast-feeding women. * Significant liver impairment. * Patients known to have active malignant disease. * Patients treated with medications that could affect lipoprotein metabolism significantly (like atypical antipsychotics, chemotherapy). * Untreated hypothyroid and hyperthyroidism (if treated and TFT normal could be recruited).